Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828956 | 0.85 | CYP3A4 (0.41) | NPC1CYP2D6CYP3A4OPRD1KCNH2 | |
| SCHEMBL828303 | 0.79 | TP53 (0.41) | NPC1CYP3A4FAAHOPRD1KCNH2 | |
| SCHEMBL9977255 | 0.75 | SMN1; SMN2 (0.45) | GRIN2BHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL829117 | 0.72 | CALCRL (0.59) | GRIN2B | |
| SCHEMBL2248124 | 0.71 | GPR119 (0.46) | OPRD1 | |
| SCHEMBL26115561 | 0.70 | GRIN2B (0.41) | GRIN2BHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL9991011 | 0.70 | SMN1; SMN2 (0.41) | GRIN2BHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL26118988 | 0.70 | SMN1; SMN2 (0.37) | GRIN2BHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL26116819 | 0.70 | SCN9A (0.41) | GRIN2BHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL23121238 | 0.69 | GRIN2B (0.40) | GRIN2BHTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271640-B1 | Piperidine derivatives as CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2271640-B1 | Piperidine derivatives as CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2271640-A2 | PIPERIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126530-A2 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126530-A2 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | GRIN2B 377/4885HTT 4342/4885SMN1; SMN2 4568/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | GRIN2B 377/4885HTT 4342/4885SMN1; SMN2 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.